HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
trastuzumab / hyaluronidase-oysk Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
HER-2 overexpression
|
Gastric Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Cancer
|
HER-2 overexpression
|
Esophageal Cancer
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
lapatinib Sensitive: B - Late Trials
|
lapatinib Sensitive: B - Late Trials
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
neratinib Sensitive: B - Late Trials
|
neratinib Sensitive: B - Late Trials
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: B - Late Trials
|
lapatinib Sensitive: B - Late Trials
|
HER-2 overexpression
|
Solid Tumor
|
HER-2 overexpression
|
Solid Tumor
|
CT-0508 Sensitive: B - Late Trials
|
CT-0508 Sensitive: B - Late Trials
|
HER-2 overexpression
|
Gallbladder Cancer
|
HER-2 overexpression
|
Gallbladder Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Endometrial Cancer
|
HER-2 overexpression
|
Endometrial Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Esophageal Cancer
|
HER-2 overexpression
|
Esophageal Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Pancreatic Cancer
|
HER-2 overexpression
|
Pancreatic Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Salivary Gland Cancer
|
HER-2 overexpression
|
Salivary Gland Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Cervical Cancer
|
HER-2 overexpression
|
Cervical Cancer
|
trastuzumab Resistant: C1 - Off-label
|
trastuzumab Resistant: C1 - Off-label
|
HER-2 overexpression
|
Urothelial Cancer
|
HER-2 overexpression
|
Urothelial Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Cholangiocarcinoma
|
HER-2 overexpression
|
Cholangiocarcinoma
|
lapatinib Sensitive: C1 - Off-label
|
lapatinib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
ASLAN001 Sensitive: C2 – Inclusion Criteria
|
ASLAN001 Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Salivary Gland Cancer
|
HER-2 overexpression
|
Salivary Gland Cancer
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HM 78136B Sensitive: C2 – Inclusion Criteria
|
HM 78136B Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Ovarian Cancer
|
HER-2 overexpression
|
Ovarian Cancer
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
CRC
|
HER-2 overexpression
|
CRC
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
NSCLC
|
HER-2 overexpression
|
NSCLC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Her-VAXX Sensitive: C2 – Inclusion Criteria
|
Her-VAXX Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Urothelial Cancer
|
HER-2 overexpression
|
Urothelial Cancer
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
eribulin mesylate Sensitive: C2 – Inclusion Criteria
|
eribulin mesylate Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Biliary Tract Cancer
|
HER-2 overexpression
|
Biliary Tract Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
CRC
|
HER-2 overexpression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Solid Tumor
|
HER-2 overexpression
|
Solid Tumor
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
disitamab vedotin Sensitive: C3 – Early Trials
|
disitamab vedotin Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
cabazitaxel Sensitive: C3 – Early Trials
|
cabazitaxel Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Endometrial Cancer
|
HER-2 overexpression
|
Endometrial Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
NSCLC
|
HER-2 overexpression
|
NSCLC
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Pancreatic Cancer
|
HER-2 overexpression
|
Pancreatic Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Bladder Cancer
|
HER-2 overexpression
|
Bladder Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Salivary Gland Cancer
|
HER-2 overexpression
|
Salivary Gland Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
AT101 Sensitive: C3 – Early Trials
|
AT101 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
CRC
|
HER-2 overexpression
|
CRC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
simvastatin Sensitive: C3 – Early Trials
|
simvastatin Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Uterine Cancer
|
HER-2 overexpression
|
Uterine Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|